CyGenica has announced that it has raised $ $1.4 million in a seed fund investment round, led by VC investor SOSV. The funding round will accelerate validation of CyGenica’s proprietary technology for intercellular drug delivery.
CyGenica’s technology addresses the problem of delivering large-molecule therapeutics into living cells without damaging them or triggering an adverse immune response.
The current investment seed round of $1.4 million was led by venture capital investor SOSV. Other investors participating in the round included the VOYAGER Health-Tech fund, David Rowan, founder of Voyagers.io, and angel investors Sharaf Yamani and Sami Mikati.
CyGenica intends to utilise the investment to accelerate the development of its drug delivery technology for genome editing, seeking to be a key partner of biopharma companies in the advancement of cutting-edge therapeutics for cancer and rare diseases to improve patient’s health and quality of life.